Gene expression studies using a cohort of 55 primary AML patient samples demonstrated in parallel a positive correlation between XBP1s, MIR22HG and XBP1s known target DNAJB9 (Fig. 5G–I). This evidence concerns the gene DNAJB9 and acute myeloid leukemia.